Detalhe da pesquisa
1.
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
Gynecol Oncol
; 185: 128-137, 2024 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38412736
2.
Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients.
Int J Gynecol Cancer
; 34(4): 574-580, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38242546
3.
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Int J Gynecol Cancer
; 34(4): 550-558, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38129136
4.
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients.
Gynecol Oncol
; 173: 98-105, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37105063
5.
A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.
Gynecol Oncol
; 171: 106-113, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36868112
6.
Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients. A TMRG and GINECO group study.
Gynecol Oncol
; 174: 190-199, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37210929
7.
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
Gynecol Oncol
; 170: 186-194, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36706645
8.
Evaluation of Scores to Reflect Toxicity Impact on Quality of Life of Patients With Platinum-Resistant Ovarian Cancer: AURELIA Substudy.
J Natl Compr Canc Netw
; 21(5): 473-479.e4, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37156482
9.
Impact of consolidation chemotherapy after delayed complete surgery in advanced epithelial ovarian cancer: a propensity score analysis.
Int J Gynecol Cancer
; 33(1): 94-101, 2023 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36517074
10.
Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial.
Gynecol Oncol
; 166(3): 494-502, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35851489
11.
Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.
Gynecol Oncol
; 166(3): 389-396, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35902297
12.
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.
Gynecol Oncol
; 166(2): 254-262, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35718565
13.
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study.
Int J Gynecol Cancer
; 32(6): 761-768, 2022 06 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35086926
14.
Predicting tumor response and outcome of second-look surgery with 18F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer.
Eur J Nucl Med Mol Imaging
; 48(6): 1998-2008, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33221969
15.
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
Gynecol Oncol
; 163(2): 274-280, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34452745
16.
Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT).
Gynecol Oncol
; 159(1): 129-135, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32723678
17.
Corrigendum to "A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer".
Gynecol Oncol
; 175: 194, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37271667
18.
[State of results of HIPEC for epithelial ovarian cancer in the primary treatment or for relapse]. / État des lieux des résultats en termes de survie de la CHIP en primo-traitement et en récidive dans le cancer épithélial de l'ovaire.
Bull Cancer
; 111(3): 261-266, 2024 Mar.
Artigo
em Francês
| MEDLINE | ID: mdl-36906402
19.
Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
Cancer Med
; 13(9): e7168, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38733172
20.
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study.
Drugs Real World Outcomes
; 10(2): 207-213, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36630055